cyrilzakka/clinical-trials huggingface dataset:
EVALUATION OF BRACHIAL PLEXUS IN DIFFERENT ARM POSITION

In daily life,people protect their tissues against ischemia by constantly changing positions. In situations that cause unconsciousness such as anesthesia,people cannot react to the stress or pressure due to immobility.This prolongation of immobility can lead to reversible or irreversible damage to the tissues.Therefore,not careful positioning in patients undergoing surgery can lead to serious complications.Peripheral nerve disorders are common in clinical practice.Electrodiagnostic studies continue to be the gold standard for the evaluation of nerve disorders.Elastography is a technique that measures the elastic properties of tissues as a new ultrasonography technology.Given the histological changes in diseased peripheral nerves, nerve elastography has begun to be studied as a noninvasive way to evaluate changes in nerve tissue composition.Elastography of the peripheral nerves has rarely been studied.

Primary aim in this study is to compare the elastography values of the brachial plexus in different arm and head positions and to contribute to elucidating the mechanism of nerve damage due to position.American Society of Anesthesiologists (ASA) I-II volunteers between the ages of 18-65 will be recruited to the study.The bilateral brachial plexus of each volunteer will be examined.Participants with upper extremity or cervical trauma, muscle weakness,cervical disc herniation or a history of spine or cranial surgery, neuromuscular disease, clinical diagnosis of brachial plexopathies, hyperlipidemia,diabetes mellitus or radiotherapy history in the cervical region,body mass index\> 35 will not be taken.Before the procedure, the muscle strength of the upper extremity and cervical muscles will be examined and volunteers with muscle weakness will be excluded from the study.Measurements will be made together by two researchers who have at least 5 years of experience in ultrasonography.Measurements will be made in 3 different positions.When the arm and head are in neutral position, the head is turned to the opposite side and the head is turned to the opposite side, the brachial plexus in the supraclavicular region will be visualized by ultrasonography while the arm is in hyperabduction.The area between the upper boundary and the lower boundary of the plexus will be marked, and the values will be taken 5 times consecutively with the share wave elastography method and the elastic modulus,shear wave velocity will be recorded.


Eligibility Criteria:
Inclusion Criteria:

* ASA I-II
* Volunteers

Exclusion Criteria:

* Upper extremity trauma
* Cervical trauma
* Muscle weakness
* Cervical disc herniation
* History of spine surgery
* Cranial surgery,
* Neuromuscular disease
* Clinical diagnosis of brachial plexopathies
* Hyperlipidemia
* Diabetes mellitus
* Radiotherapy history in the cervical region
* Severely obese volunteers (body mass index\> 35 kg / m2)
A Study of Ponesimod in Healthy Adult Participants

The purpose of this study is to evaluate the effect of steady-state carbamazepine (CBZ; a strong pregnane X receptor \[PXR\] agonist) on the pharmacokinetics (PK) of ponesimod following a gradual up-titration regimen in healthy adult participants.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index between (BMI) 18-30 kilograms per meter square (kg/m\^2)
* Willing and able to adhere to the prohibitions and restrictions.
* Female participants with negative pregnancy test.
* Women of childbearing potential (WOCBP) must use 2 methods of contraception.
* Healthy on the basis of physical examination (including neurological examination and skin examination), Columbia suicide severity rating scale questionnaire (C-SSRS) questionnaire, ophthalmological examination, medical history, vital signs, and 12-lead electrocardiogram (ECG).
* Positive varicella zoster virus (VZV).

Exclusion Criteria:

* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 60 milliliter per minute \[mL/min\]), thyroid disease, neurologic or psychiatric disease, confirmed or suspected macular edema, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
* Contraindications to the use of Carbamazepine (CBZ) as per local prescribing information
* Any immunosuppressive treatment within 6 weeks before first study drug administration.
* Lymphopenia (less than 1,000 cells per microliter).
* Received an investigational drug or used an invasive investigational medical device within 30 days before the first study drug intake or received a biological product within 3 months or 5 half-lives (whichever is longer) before the first study drug intake, or is currently enrolled in an investigational study.
* Lack of good/reasonable venous access.
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
The Immediate Physiological and Perceptual Response to Blood-flow Restricted Strength Training with Eccentric Loading

Decreasing workloads in strength training makes it more tolerable for a broad range of people. When designed as blood-flow restriction training, similar gains in strength and muscle mass are achieved compared to traditional training. Adding high training loads to blood-flow restriction training only in the eccentric phase (BFR-ECC) might achieve superior gains in muscle strength while still maximizing tolerability of the training stimuli.

This study aims to investigate the acute physiological and perceptual response of blood-flow restriction training with eccentric loading in comparison to traditional eccentric training. The study recruits healthy individuals ≥ 18 years.


Eligibility Criteria:
Inclusion Criteria:

* Clinically Healthy

Exclusion Criteria:

* Physical or intellectual impairment precluding informed consent or protocol adherence
* Pain during exercise of any origin
* History of thromboembolic event in the lower extremity
* Known pregnancy (no testing is carried out)
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.

This is a single arm, open label, clinical trial to evaluate the feasibility and safety of oral tazemetostat followed by standard of care CAR T cell infusion in previously treated DLBCL, FL, and MCL. The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety.

Tazemetostat 800 mg will be given twice daily by mouth for at least 1 week prior to apheresis, during the period between apheresis and CAR T infusion, and following lymphodepletion chemotherapy until Day 7 post-CAR T therapy. Once patients' platelets and neutrophil counts recover, tazemetostat will be resumed. Tazemetostat treatment will continue for up to 6 months in patients with complete responses and up to 12 months in patients with partial responses.

A 3+3 trial design will be implemented for the first six patients enrolled. The regimen will be considered feasible if at least 12 out of 15 subjects are able to receive at least 2 weeks of tazemetostat, generate the CAR T cell product and receive CAR T cell therapy.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of DLBCL, FL, or MCL
* Eligible to receive standard of care CAR T cells
* Have received at least 1 prior therapies

Exclusion Criteria:

* Active viral infection with HIV or hepatitis type B or C
* Active, uncontrolled systemic fungal, bacterial or viral infection
* Active treatment for another cancer
* Pregnant or breastfeeding
* Unable to take oral medication
* Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine

The purpose of this study is to determine whether N-acetylcysteine is effective in the prevention of hearing loss in both ears due to aminoglycoside and/or vancomycine induced ototoxicity in peritoneal dialysis patients.


Eligibility Criteria:
Inclusion Criteria:

* End-stage renal disease
* Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy
* Clinical diagnosis of a peritonitis episode in a continuous ambulatory peritoneal dialysis patient
* Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode

Exclusion Criteria:

* Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months
* Detection of mechanical occlusion of external ear
* Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry
* History of a continuous ambulatory peritoneal dialysis related peritonitis
Triomune Bioequivalence With Innovators

The null hypothesis is that there is a difference in the the relative rate and extent of absorption into the systemic circulation of Triomune and brand-name Stavudine/Lamivudine/Nevirapine in HIV-infected Africans and the alternative hypothesis is that there is no difference in the the relative rate and extent of absorption into the systemic circulation of Triomune and brand-name Stavudine/Lamivudine/Nevirapine in HIV-infected Africans. This is a non-inferiority study.

Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings, yet there is little evidence confirming the bioequivalence of generic and brand name formulations. We compared the steady-state pharmacokinetics of Lamivudine, Stavudine and Nevirapine in HIV-infected subjects who were receiving a generic formulation (Triomune®) or the corresponding brand formulations (Epivir®, Zerit®, and Viramune®). An open-label, randomized, crossover study was carried out in 18 HIV-infected Ugandan subjects stabilized on Triomune-40. Subjects received Lamivudine (150 mg), Stavudine (40 mg), and Nevirapine (200 mg) in either the generic or brand formulation twice a day for 30 days, before switching to the other formulation. At the end of each treatment period, blood samples were collected over 12 h for pharmacokinetic analysis. The main outcome measures were the mean AUC0-12h and Cmax. Bioequivalence was defined as a geometric mean ratio between the generic and brand-name within the 90% confidence interval of 0.8-1.25.

Eligibility Criteria:
Inclusion Criteria:

1. HIV-infected men and non-pregnant women;
2. On Triomune for at least 4 weeks;
3. 18 years or greater;
4. Residing within 15km of Kampala city center

Exclusion Criteria:

1. Unable to sign or understand informed consent
2. Concurrent medication known to interact with any of the components of Triomune
3. Patients with active TB, malabsorption, nausea, emesis, abdominal discomfort, chronic diarrhoea, documented active clinically relevant hepatitis;
4. Patients expected to change their drug regimen or dosage during the study
5. Those planning to move out of Kampala in the next two months;
6. Hemoglobin \<7.0 mmol/l (men) or \<6.5 mmol/l (women);
7. Alanine aminotransferase or aspartate aminotransferase \>5 times the upper limit of normal;
8. Serum creatinine \> 1.5 times the upper limit of normal
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.


Eligibility Criteria:
Inclusion Criteria:

* Male or female of any race
* Between the ages of 18 and 75 years
* Knee Pain due to osteoarthritis

Exclusion Criteria:

* Pregnant
* Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline
* History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year
Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1

Flavanols are plant-derived compounds commonly present in the human diet. Examples of flavanol-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts. The consumption of flavanol-containing foods and beverages has been associated with improvements in cardiovascular health. In this study, the investigators hope to learn more about the effects of the consumption of increasing amounts of cocoa flavanols on blood pressure, platelet function and other metabolic parameters in healthy humans. This study was followed by a second study that aimed at investigating the effects of long term consumptions of cocoa flavanols on blood pressure, platelet function and other metabolic parameters in healthy humans.


Eligibility Criteria:
Inclusion Criteria:

* 30-55 years old
* A normal blood chemistry and liver function
* BMI \< 30 kg/m2
* previously consumed cocoa and peanut products, with no adverse reactions

Exclusion Criteria:

* A history of cardiovascular disease, stroke, hypertension, renal, hepatic, or thyroid disease, GI tract disorders, previous GI surgery, metabolic syndrome, diabetes, taking cholesterol-lowering medication, hormone replacement therapy, antioxidant supplements, on aspirin therapy or taking anticoagulants, or on a medically prescribed diet.
* Allergies to nuts, cocoa and chocolate products
* Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or using herbal dietary supplements
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).


Eligibility Criteria:
* Key Inclusion Criteria

  * Japanese participants ≥ 18 years of age upon entry into initial screening
  * Palmoplantar pustulosis diagnosis with or without pustulotic arthro-osteitis (PAO) for no less than 24 weeks
  * PPPASI total score of ≥12 at screening and at baseline
  * Moderate or severe pustules/vesicles on palms or soles (PPPASI severity score ≥2) at screening and at baseline
  * Inadequate response (defined as repeated relapsing-remitting in the same location for a 24-week period) to topical treatments prior to or at screening
* Key Exclusion Criteria

  * Changes in disease severity during screening (PPPASI total score change ≥ 5 improvement, from screening to baseline)
  * Periodontitis requiring treatment
  * Chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment
  * Has a diagnosis of plaque-type psoriasis at baseline
  * Has the presence of pustular psoriasis on any part of the body other than the palms and soles
  * Has evidence of skin conditions of hand and feet at baseline that would interfere with evaluations of the effect of Investigational Product
  * Has unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within 12 weeks prior to screening
  * Malignancy or history of malignancy
  * Participant has received any procedures for focal infection within 24 weeks of baseline
  * Female participants who are breastfeeding or who plan to breastfeed while on study
  * Female participants of childbearing potential with a positive pregnancy test
  * Had prior treatment with apremilast
  * Has a prior medical history of suicide attempt at any time in the participant's lifetime prior to signing of informed consent or randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing of informed consent
24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol

The proposed crossover study will compare for the first time the quality of 24-hour intraocular pressure control with the combination of travoprost and brinzolamide/timolol compared with travoprost and brimonidine/timolol in glaucoma patients insufficiently controlled with travoprost. This comparison may determine the real efficacy of the two fixed combinations when added to the prostaglandin. The design of the proposed study should facilitate a better understanding of the role of these medications in glaucoma management.


Eligibility Criteria:
Inclusion Criteria:

* Patient has open-angle glaucoma and is older than 29 years
* Patients should exhibit typical disc, or field changes and an untreated morning IOP greater than 25 mm Hg
* Patients are treated for at least 3 months with travoprost and should have demonstrated at least a 20% morning IOP reduction
* Patient deemed by PI to require adjunctive therapy to obtain desired target IOP
* Patient should exhibit IOP greater than 18 mm Hg on travoprost monotherapy (2 separate IOP readings at 10:00)
* Patient has mild to moderate glaucoma (field loss more than 16 dB; cupping 0.8 or less)
* Distance best corrected Snellen visual acuity at least 0.1
* No contraindications to travoprost, brimonidine, brinzolamide and β-blockers
* No history of lack of response (\<10% morning IOP reduction) to any medication
* Patient can understand the instructions and adhere to medications

Exclusion Criteria:

* Female patient of childbearing potential or lactating mother
* History of trauma, inflammation, surgery
* History of past use of steroids (within 2 months), severe dry eyes and use of contact lenses
* Signs of ocular infection, except blepharitis
* Evidence of corneal abnormality that may affect IOP measurements etc
* Closed angle
* History of non-compliance
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.

Past research on the use of the NTP, atypical antipsychotics, and bupropion in schizophrenic individuals to aid in smoking cessation has been encouraging. The purpose of this study is to compare bupropion SR to a placebo to determine its effectiveness when used in combination with an NTP to help schizophrenic individuals quit smoking.

Participants in this double-blind, placebo-controlled study will be randomly assigned to receive either the NTP (21 mg/day) and placebo or the NTP and bupropion SR (300 mg/day). Participants will begin taking one pill each day of bupropion SR (150 mg/day) or placebo at the start of the second week of the study. After three days, the dose of bupropion SR or placebo will increase to 2 pills each day. Participants will continue this dosing regimen until the end of Week 10. Throughout the 10-week study, participants will receive weekly group therapy.

Eligibility Criteria:
Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence
* Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5
* Smokes at least 20 cigarettes per day (1 pack per day)
* Expired breath CO level \> 10 ppm and cotinine level \> 210 ng/ml at the baseline measurement
* Currently taking a stable dose of antipsychotic
* Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation

Exclusion Criteria:

* Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month
* History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)
* Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern (e.g., a history of severe heart, liver, or kidney disease or diabetes mellitus)
* Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)
* Currently taking diabetes mellitus medications, St. John's Wort, appetite suppressants, ephedrine-containing medications, theophylline, clonidine, reserpine, methyldopa, or anti-anginal medications (e.g., beta-blockers, calcium channel blockers, nitroglycerin preparations)
* History of schizoaffective disorder and not stabilized on a mood stabilizer (e.g., lithium, valproate, carbamazepine)
Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial

This is a multi-center, randomized, double-masked clinical trial. All study devices are market approved/cleared in the localities where the study is conducted. Subjects will be randomly assigned to wear NaturalVue Sphere single vision contact lenses (SVCL) or NaturalVue Multifocal (NVMF) soft contact lenses for a total of three years.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female, aged 7 to \<13 (inclusive) at the Screening/Baseline examination.
2. Meet the following refractive criteria determined by cycloplegic autorefraction at Screening/Baseline:

   * Spherical Equivalent Refractive Error (SERE): between -0.75 and -5.00 D inclusive.
   * Astigmatism: ≤ -0.75 D
   * Anisometropia: \< 1.000

Exclusion Criteria:

1. Has previously worn or currently wears rigid or gas permeable contact lenses, including orthokeratology lenses,
2. Appears to exhibit poor personal hygiene, that, in the Investigator's opinion, might prevent safe contact lens wear.
3. Is currently, or within 30 days prior to this study has been, an active participant in another clinical study.
4. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine, multifocal or specialized contact lenses, or ANY other myopia control treatment.
5. The Investigator for any reason considers that it is not in the best interest of the subject to participate in the study, including if the child is not mature enough to independently handle and care for soft contact lenses.